Vol 91, No 5 (2020)
Research paper
Published online: 2020-05-29

open access

Page views 1489
Article views/downloads 1589
Get Citation

Connect on Social Media

Connect on Social Media

Decorin levels in early- and late-onset preeclampsia

Gülten Özgen1, Gültekin Adanaş Aydın1
Pubmed: 32495932
Ginekol Pol 2020;91(5):262-268.

Abstract

Objectives: Preeclampsia (PE) is a pregnancy complication caused by typically limited proliferation, apoptosis, migration,
and invasion of extra-trophoblast cells. Decorin (DCN) is a decidua-derived transforming growth factor (TGF)-binding
proteoglycan which exerts multiple physiological functions such as collagen fibrillogenesis, myogenesis, angiostasis, and
restraining placental invasiveness by adversely regulate proliferation, migration, and invasiveness of human extravillous
trophoblast cells. Preeclampsia is mainly classified as early- and late-onset PE according to the timing of the disease onset.
In the present study, we aimed to investigate the DCN levels in early-onset PE (EOPE, < 34 weeks) and late-onset severe PE
(LOPE, ≥ 34 weeks) and uncomplicated pregnancies.
Material and methods: In this case-control study, serum samples were obtained from 21 pregnant women with EOPE
and 29 pregnant women with LOPE, as well as from 38 healthy controls (n = 12 early-onset controls and n = 26 late-onset
controls) with uncomplicated pregnancies.
Results: The mean DCN level was statistically significantly higher in the early-onset PE controls than late-onset PE controls
(p = 0.040). Although the mean DCN level was higher in the early-onset PE controls than EOPE and LOPE groups, it did not
reach statistical significance (p = 0.119 and p = 0.117, respectively).
Conclusions: Although DCN has been thought to play a role in the pathophysiology of PE, our study results show that DCN
is not a useful predictive marker of EOPE and LOPE. Further large-scale studies are needed to draw a definitive conclusion.

Article available in PDF format

View PDF Download PDF file

References

  1. Wallis AB, Saftlas AF, Hsia J, et al. Secular trends in the rates of preeclampsia, eclampsia, and gestational hypertension, United States, 1987-2004. Am J Hypertens. 2008; 21(5): 521–526.
  2. Saleem S, McClure EM, Goudar SS, et al. Global Network Maternal Newborn Health Registry Study Investigators. A prospective study of maternal, fetal and neonatal deaths in low- and middle-income countries. Bull World Health Organ. 2014; 92(8): 605–612.
  3. Lisonkova S, Sabr Y, Mayer C, et al. Maternal morbidity associated with early-onset and late-onset preeclampsia. Obstet Gynecol. 2014; 124(4): 771–781.
  4. Stepan H, Unversucht A, Wessel N, et al. Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion. Hypertension. 2007; 49(4): 818–824.
  5. Krusius T, Ruoslahti E. Primary structure of an extracellular matrix proteoglycan core protein deduced from cloned cDNA. Proc Natl Acad Sci U S A. 1986; 83(20): 7683–7687.
  6. Schaefer L, Iozzo RV. Biological functions of the small leucine-rich proteoglycans: from genetics to signal transduction. J Biol Chem. 2008; 283(31): 21305–21309.
  7. Reed CC, Iozzo RV. The role of decorin in collagen fibrillogenesis and skin homeostasis. Glycoconj J. 2002; 19(4-5): 249–255.
  8. Kinsella MG, Bressler SL, Wight TN. The regulated synthesis of versican, decorin, and biglycan: extracellular matrix proteoglycans that influence cellular phenotype. Crit Rev Eukaryot Gene Expr. 2004; 14(3): 203–234.
  9. Iacob D, Cai J, Tsonis M, et al. Decorin-mediated inhibition of proliferation and migration of the human trophoblast via different tyrosine kinase receptors. Endocrinology. 2008; 149(12): 6187–6197.
  10. Gogiel T, Galewska Z, Romanowicz L, et al. Pre-eclampsia-associated alterations in decorin, biglycan and versican of the umbilical cord vein wall. Eur J Obstet Gynecol Reprod Biol. 2007; 134(1): 51–56.
  11. Siddiqui MF, Nandi P, Girish GV, et al. Decorin over-expression by decidual cells in preeclampsia: a potential blood biomarker. Am J Obstet Gynecol. 2016; 215(3): 361.e1–361.e15.
  12. van der Merwe JL, Hall DR, Wright C, et al. Are early and late preeclampsia distinct subclasses of the disease--what does the placenta reveal? Hypertens Pregnancy. 2010; 29(4): 457–467.
  13. Xu G, Guimond MJ, Chakraborty C, et al. Control of proliferation, migration, and invasiveness of human extravillous trophoblast by decorin, a decidual product. Biol Reprod. 2002; 67(2): 681–689.
  14. Zhu JY, Pang ZJ, Yu YH. Regulation of trophoblast invasion: the role of matrix metalloproteinases. Rev Obstet Gynecol. 2012; 5(3-4): e137–e143.
  15. Huppertz B, Frank HG, Kingdom JC, et al. Villous cytotrophoblast regulation of the syncytial apoptotic cascade in the human placenta. Histochem Cell Biol. 1998; 110(5): 495–508.
  16. Nandi P, Siddiqui MF, Lala PK. Restraint of Trophoblast Invasion of the Uterus by Decorin: Role in Pre-eclampsia. Am J Reprod Immunol. 2016; 75(3): 351–360.
  17. Nandi P, Lim H, Torres-Garcia EJ, et al. Human trophoblast stem cell self-renewal and differentiation: Role of decorin. Sci Rep. 2018; 8(1): 8977.
  18. Weber M, Göhner C, San Martin S, et al. Unique trophoblast stem cell- and pluripotency marker staining patterns depending on gestational age and placenta-associated pregnancy complications. Cell Adh Migr. 2016; 10(1-2): 56–65.
  19. Tan KH, Tan SS, Ng MJ, et al. Extracellular vesicles yield predictive pre-eclampsia biomarkers. J Extracell Vesicles. 2017; 6(1): 1408390.
  20. Cağlar M, Yavuzcan A, Göksu M, et al. Decorin: a possible marker for fetal growth restriction. Gynecol Endocrinol. 2014; 30(2): 141–144.
  21. Murthi P, van Zanten DE, Eijsink JJH, et al. Decorin expression is decreased in first trimester placental tissue from pregnancies with small for gestation age infants at birth. Placenta. 2016; 45: 58–62.
  22. Swan BC, Murthi P, Rajaraman G, et al. Decorin expression is decreased in human idiopathic fetal growth restriction. Reprod Fertil Dev. 2010; 22(6): 949–955.